Skip to main content
Representatives from The University of Toledo and the U.S. Department of Energy’s Oak Ridge National Laboratory (ORNL) in Tennessee are teaming up to conduct collaborative automotive materials research.” Credit: University of Toledo

ORNL and The University of Toledo have entered into a memorandum of understanding for collaborative research.

low-cost material can be used as an additive to increase thermal insulation performance

Quanex Building Products has signed a non-exclusive agreement to license a method to produce insulating material from ORNL. The low-cost material can be used as an additive to increase thermal insulation performance and improve energy efficiency when applied to a variety of building products.

early prototype of the optical array developed by Oak Ridge National Laboratory.

IDEMIA Identity & Security USA has licensed an advanced optical array developed at Oak Ridge National Laboratory. The portable technology can be used to help identify individuals in challenging outdoor conditions.

Snowflakes indicate phases of super-cold ice

An ORNL-led team's observation of certain crystalline ice phases challenges accepted theories about super-cooled water and non-crystalline ice. Their findings, reported in the journal Nature, will also lead to better understanding of ice and its various phases found on other planets, moons and elsewhere in space.

Illustration of the intricate organization of the PKA structure, wherein different parts of the protein are connected through elaborate hydrogen bonding networks (dashed yellow lines), glued together by the hydrophobic assemblies (light blue and orange volumes)—all working together to build the functional active site. Insert shows protonation of the transferred phosphoryl group (cyan mesh) and its many interactions with water and the active site amino acid residues. Credit: Jill Hemman/ORNL

OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.